Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
GSRX Industries Inc. (GSRX)
Dorado, PR, US
GSRX Industries Inc., functioning through its various subsidiaries, primarily operates within the retail cannabis sector. Its core activities involve the acquisition, development, and management of cannabis dispensaries. The company currently oversees five cannabis dispensaries in Puerto Rico, all operating under the Green Spirit RX brand. Additionally, it manages one dispensary in California, known as The Green Room. Beyond its physical retail outlets, GSRX also owns and runs GetPureAndNatural.com, an online platform dedicated to selling a variety of hemp extract products. Its scope of business further extends to the full vertical integration of cannabis and cannabinoid products, covering their extraction, manufacturing, distribution, and final delivery. In July 2018, the company changed its name from Green Spirit Industries Inc. to its current designation, GSRX Industries Inc. Its main corporate office is located in Dorado, Puerto Rico.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -50.00% | -99.83% | -99.99% | -99.95% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+310.4% ★ Q3'20: -0.4% (vs Q3'19)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-51.4% Q3'20: +90.9% (vs Q3'19)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-198.5% Q3'20: +18.3% (vs Q3'19)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-204.2% Q3'20: -71.6% (vs Q3'19)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-333.7% Q3'20: -195.8% (vs Q3'19)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+49.4% Q3'20: +10.8% (vs Q3'19)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.11× Q3'20: -0.19× (vs Q3'19)
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Capital Management Limited | 4.00M | 80.80% | 4.00M | — | 4.00M | 10.00 | CO | Channel Islands | 2008-05-05 | ↗ |
| 2 | C. Zachariou | 1.80M | 6.00% | 1.80M | — | 1.80M | — | CO | Kingdom | 2017-07-25 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2008-05-05 | FOUNTAINHEAD CAPITAL MANAGEMENT LTD | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 4,000,000 | — | ↗ |
| 2008-05-05 | Alison Geoffrey | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2007-12-31 | CASDEN HENRY C. | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2007-10-01 | CASDEN HENRY C. | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 4,000,000 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Thomas J. Gingerich | Chief Financial Officer & Secretary | 85.0K | male |
| Jeffrey Bryan Jump | Non-Executive Board Advisory Consultant & Member of Advisory Board | — | male |
| Troy Nihart | Chairman, President & Interim Chief Executive Officer | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GSRX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
